Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer.
Palmieri C, Szydlo R, Miller M, Barker L, Patel NH, Sasano H, Barwick T, Tam H, Hadjiminas D, Lee J, Shaaban A, Nicholas H, Coombes RC, Kenny LM. Palmieri C, et al. Among authors: hadjiminas d. Breast Cancer Res Treat. 2017 Nov;166(2):527-539. doi: 10.1007/s10549-017-4427-x. Epub 2017 Aug 9. Breast Cancer Res Treat. 2017. PMID: 28795252 Free PMC article. Clinical Trial.
Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.
Polychronis A, Sinnett HD, Hadjiminas D, Singhal H, Mansi JL, Shivapatham D, Shousha S, Jiang J, Peston D, Barrett N, Vigushin D, Morrison K, Beresford E, Ali S, Slade MJ, Coombes RC. Polychronis A, et al. Among authors: hadjiminas d. Lancet Oncol. 2005 Jun;6(6):383-91. doi: 10.1016/S1470-2045(05)70176-5. Lancet Oncol. 2005. PMID: 15925816 Clinical Trial.
Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer.
Patten DK, Corleone G, Győrffy B, Perone Y, Slaven N, Barozzi I, Erdős E, Saiakhova A, Goddard K, Vingiani A, Shousha S, Pongor LS, Hadjiminas DJ, Schiavon G, Barry P, Palmieri C, Coombes RC, Scacheri P, Pruneri G, Magnani L. Patten DK, et al. Nat Med. 2018 Sep;24(9):1469-1480. doi: 10.1038/s41591-018-0091-x. Epub 2018 Jul 23. Nat Med. 2018. PMID: 30038216 Free PMC article.
An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study).
Coombes RC, Tat T, Miller ML, Reise JA, Mansi JL, Hadjiminas DJ, Shousha S, Elsheikh SE, Lam EW, Horimoto Y, El-Bahrawy M, Aboagye EO, Contractor KB, Shaw JA, Walker RA, Marconell MH, Palmieri C, Stebbing J. Coombes RC, et al. Among authors: hadjiminas dj. Ann Oncol. 2013 Apr;24(4):924-30. doi: 10.1093/annonc/mds594. Epub 2012 Dec 11. Ann Oncol. 2013. PMID: 23233650 Free article. Clinical Trial.
Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial.
Coombes RC, Tovey H, Kilburn L, Mansi J, Palmieri C, Bartlett J, Hicks J, Makris A, Evans A, Loibl S, Denkert C, Murray E, Grieve R, Coleman R, Borley A, Schmidt M, Rautenberg B, Kunze CA, Rhein U, Mehta K, Mousa K, Dibble T, Lu XL, von Minckwitz G, Bliss JM; Randomized European Celecoxib Trial (REACT) Trial Management Group and Investigators. Coombes RC, et al. JAMA Oncol. 2021 Sep 1;7(9):1291-1301. doi: 10.1001/jamaoncol.2021.2193. JAMA Oncol. 2021. PMID: 34264305 Free PMC article. Clinical Trial.
Assessment of Technical Skills in Axillary Lymph Node Dissection.
Muthuswamy K, Fisher R, Mavroveli S, Petrou F, Khawar S, Amlani A, Hanna GB, Hadjiminas DJ, Thiruchelvam PTR, Leff DR. Muthuswamy K, et al. Ann Surg. 2022 Mar 1;275(3):e568-e574. doi: 10.1097/SLA.0000000000003946. Ann Surg. 2022. PMID: 32590540
72 results